DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics (Nasdaq: DMAC) will host an October 23, 2026 webinar presenting preliminary Phase 2 findings for DM199 in early-onset fetal growth restriction. The virtual event begins at 8:00 AM EDT and will cover interim safety, tolerability and clinical findings from the first six treated participants. Principal investigator Catherine Cluver will present the results, followed by an expert panel discussion and live questions.
First-cohort enrollment is complete at 5 µg/kg, and dosing has begun in the second cohort at 10 µg/kg. The investigator-sponsored study at Tygerberg Hospital in Cape Town is open-label, single-center and single-arm, meaning it has no comparison group. It evaluates repeated injections under the skin until delivery in up to 30 participants with early-onset fetal growth restriction, across up to three dose levels.
DiaMedica Therapeutics (DMAC) will participate in four investment bank healthcare conferences in New York in September 2026.
Management will attend the Citi Biopharma Back to School Summit on September 9–10, the Cantor Global Healthcare Conference on September 9–11 (including a fireside chat on September 11 at 10:20 a.m. ET), the Lake Street 10th Annual BIG10 Conference on September 10, and the HC Wainwright 28th Annual Global Investment Conference on September 14–16, featuring a company presentation on September 15 at 1:30 p.m. ET.
DiaMedica Therapeutics (Nasdaq: DMAC) reported second quarter 2026 results and key clinical progress for lead candidate DM199 in preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke (AIS). Cash, cash equivalents and short‑term investments were $43.5 million at June 30, 2026, which the company expects will fund operations through 2027.
In late‑onset preeclampsia Phase 2 Part 1a, DM199 produced statistically significant, sustained blood pressure reductions, including a mean 29.1 mmHg systolic and 17.0 mmHg diastolic decrease at five minutes post‑infusion in the highest‑dose cohorts (n=15). Enrollment of the first six‑patient cohort in the early‑onset FGR Phase 2 study is complete, and a KOL call with topline data is planned for September.
For AIS, the ReMEDy2 Phase 2/3 trial has surpassed 85% of the 200 participants needed for a prespecified interim analysis, expected in early 2027. R&D expenses rose to $8.2 million in Q2 2026, contributing to a quarterly net loss of $10.1 million.
DiaMedica Therapeutics (Nasdaq: DMAC) plans to release its second quarter 2026 financial results after market close on Monday, August 10, 2026. The company will host a live conference call and webcast on Tuesday, August 11, 2026 at 8:00 AM EDT / 7:00 AM CDT to discuss the results and provide a business update.
Investors can access the call via dial-in at (646) 357-8766 using Conference ID 2224408, or through a webcast at https://app.webinar.net/d01wEPk9peA. A webcast replay will be available on DiaMedica’s website for 12 months, and a telephonic replay will be accessible until August 18, 2026 at (800) 770-2030 with passcode 2224408#.
DiaMedica Therapeutics (Nasdaq: DMAC) granted stock options to purchase an aggregate of 160,000 common shares on July 15, 2026 to a newly hired non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
According to DiaMedica, the options were issued under its Amended and Restated 2021 Employment Inducement Incentive Plan, have a $7.64 exercise price (the July 15, 2026 closing price), a 10-year term, and vest 25% after one year with the remaining 75% vesting in 12 quarterly installments, subject to continued service.
DiaMedica Therapeutics (Nasdaq: DMAC) reported dosing the first two patients in an investigator-sponsored Phase 2 trial of DM199 for early-onset fetal growth restriction (FGR). The open-label, single-arm study will assess three dose levels in up to 30 patients. DM199 aims to improve maternal uterine blood flow without crossing into fetal circulation. DiaMedica also released a white paper reviewing the scientific basis for DM199 in FGR.
DiaMedica Therapeutics (Nasdaq: DMAC) received written FDA feedback on nonclinical data needed to advance DM199 for preeclampsia. The FDA indicated a prior rat reproductive toxicity study may support a U.S. IND if drug exposure, enzymatic activity, and pharmacologic effect in rats are adequately demonstrated.
DiaMedica will run a new rat pharmacokinetic and activity study, summarize recent data, and submit the package to FDA, while planning to initiate a preeclampsia study in Canada and the UK later in 2026.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharma company focused on preeclampsia, fetal growth restriction and acute ischemic stroke, will present at the Jefferies Global Healthcare Conference 2026 in New York.
The corporate presentation is scheduled for Thursday, June 4, 2026 at 3:45 PM ET.
DiaMedica Therapeutics (Nasdaq: DMAC) reported that its pivotal Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke has reached 75% of the 200-patient enrollment needed to trigger a pre-specified interim analysis.
An independent DSMB will review the first 200 patients before year-end 2026 and may recommend a final sample size between 300 and 728 patients. ReMEDy2 is a randomized, double-blind, placebo-controlled study, with stroke recovery at Day 90 (mRS 0–1) as the primary endpoint. Approximately 70 sites are active across the United States, Canada, the United Kingdom and Europe.
DiaMedica Therapeutics (Nasdaq: DMAC) will participate in the 2026 RBC Capital Markets Global Healthcare Conference in New York City. President and CEO Rick Pauls is scheduled for a fireside chat on Tuesday, May 19, 2026, from 4:05–4:30 PM ET, with additional one-on-one investor meetings available.